key: cord-0762787-czlg99aa authors: Sánchez, Julienne; Cohen, Melissa; Zapater, Joseph L.; Eisenberg, Yuval title: Primary Adrenal Insufficiency After COVID-19 Infection date: 2021-11-14 journal: AACE Clin Case Rep DOI: 10.1016/j.aace.2021.11.001 sha: ded2ebcfcc5ab1db587075fdfd1f4a73d2dfaa92 doc_id: 762787 cord_uid: czlg99aa BACKGROUND/OBJECTIVE: The multisystemic effects of COVID-19 are clearly becoming evident. In the adrenal gland, adrenal hemorrhage and infarction after COVID-19 infection have been reported. Our objective is to present a case of autoimmune adrenal insufficiency diagnosed post-COVID-19 infection, without evidence of hemorrhage or infarction. CASE REPORT: 64-year-old woman with hypothyroidism and type 2 diabetes presented with a 1-week history of abdominal pain, nausea, and vomiting. She experienced an asymptomatic COVID-19 infection five months prior and reported an unintentional 30-pound weight loss. Home medications were enalapril, atorvastatin and levothyroxine. Physical exam was notable for hypotension, epigastric tenderness, and mucocutaneous hyperpigmentation. Labs revealed serum sodium 117 mmol/L (135-145), TSH 0.33 μIU/mL (0.35-4.00), free T4 1.4 ng/dL (0.6-1.7), serum osmoles 253 mOsm/kg (279-300), urine osmoles 324 mOsm/kg (300-900) and urine sodium 104 mmol/L. Morning cortisol was 2.6 μg/dL (ref: >18). A high-dose 250 mcg ACTH stimulation test followed; cortisol levels returned 2.3, 2.9, and 2.6 μg/dl (ref: >18) at baseline, 30, and 60 minutes. ACTH level was 1944 pg/ml (7.2-63.3), aldosterone was <3.0 ng/dl (4.0-31.0), anti-21-hydroxylase antibody was positive (ref: neg). CT scan of the adrenals was unremarkable. Hypotension and hyponatremia resolved after initiation of intravenous hydrocortisone, and she was discharged on hydrocortisone and fludrocortisone. DISCUSSION: The patient’s symptoms, elevated ACTH, low cortisol, and presence of 21-hydroxylase antibodies, are consistent with Addison’s disease. COVID-19 may have contributed to rapid clinically-relevant disease progression after infection. CONCLUSION: The development of autoimmune Addison’s disease in the patient may be related to a prior COVID-19 infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), officially named as coronavirus disease-2019 (COVID-19), is a novel human pathogen reported to originate in Wuhan, China, around December 2019 (1) . The major organ system affected is the respiratory system, with viral spread occurring predominately through respiratory droplets and in which disease severity varies broadly from asymptomatic disease to acute respiratory distress syndrome (ARDS), multi-organ failure and death (2) . Following its discovery, however, it became clear that COVID-19 not only causes a respiratory infection but was also responsible for many disease-related syndromes due to its ability to affect various organs and tissues, including the lungs, heart, blood vessels, brain, liver, gastrointestinal tract, kidney, and multiple organs within the endocrine system (3, 4) . The short-and long-term effects of COVID-19 infection on the endocrine system are beginning to be known and remain an area of active research. Several case reports have documented the onset of adrenal insufficiency (AI) after COVID-19 infection through adrenal hemorrhage or infarction (5, 6) , however, the full effects of the infection on cortisol dynamics remains poorly understood. Here, we present a patient with no prior history of adrenal pathology or glucocorticoid use, who was diagnosed with clinically evident AI after recovery from COVID-19 infection, and whose clinical infection course and imaging modalities were not consistent with adrenal hemorrhage, hypercoagulability, or adrenal infarction. Interestingly, the patient was found to have anti-21-hydroxylase antibodies consistent with immune-mediated Addison's disease in the COVID-19 sequelae. Our report suggests a potential link between the development of clinically significant autoimmune adrenal insufficiency (AAI) and COVID-19 infection. A 64-year-old woman with type 2 diabetes and hypothyroidism, without prior glucocorticoid use or Addison's disease diagnosis, presented with abdominal pain, nausea, and vomiting for one week. Home medications include levothyroxine 100 mcg daily, atorvastatin 10 mg daily and enalapril 2.5 mg twice a day. She has no family history of autoimmune disorders and no prior surgeries. She experienced an asymptomatic COVID-19 infection five months prior and reported an unintentional 30-lb weight loss since then. Within the last five months post-COVID-19 infection, the patient presented to another hospital twice with nausea, vomiting, and poor oral intake. She was admitted each time for these symptoms and was subsequently found to have a low sodium level thought to be due to syndrome of inappropriate antidiuretic hormone (SIADH) secretion. She was discharged home after sodium levels corrected with fluid restriction. On physical exam, the patient's blood pressure was 93/66, epigastric tenderness and hyperpigmentation of the oral mucosa were noted. Blood tests showed a sodium level of 117 mEq/L (135-145 mEq/L), TSH 0.33 μIU/mL (0.35-4.00 μIU/mL), free T4 1.4 ng/dL (0.6-1.7 ng/dL), urine sodium 104 mmol/L, and osmotic concentrations in the serum of 253 mOsm/kg (279-300 mOsm/kg) and in the urine of 324 mOsm/kg (300-900 mOsm/kg). These labs were consistent with hypoosmolar hyponatremia (Table 1) . On adrenal function assessment, the patient's 8AM cortisol level was 2.6 μg/dL (Ref: >18 μg/dL). A high-dose 250 mcg ACTH stimulation test was performed; cortisol levels returned at 2.3, 2.9, and 2.6 μg/dL (ref: >18 μg/dL) at baseline, 30, and 60 minutes, respectively. Follow up labs showed an ACTH level of 1944 pg/mL (7.2-63.3 pg/mL) and an aldosterone level of <3 ng/mL (4.0-31.0 pg/mL) ( Table 2 ). Abdominopelvic CT imaging showed unremarkable adrenal glands ( Figure 1 ). An anti-21-hydroxylase antibody level was positive without a specific value J o u r n a l P r e -p r o o f reported (ref: negative, ARUP Laboratories) ( Table 2 ). Hypotension and hyponatremia resolved after initiation of intravenous hydrocortisone 25 mg every eight hours. Her clinical status significantly improved, the glucocorticoid was weaned, and the patient was discharged in stable condition on hydrocortisone 30 mg daily and fludrocortisone 0.05 mg daily. Our patient presented with hyponatremia and biochemical evidence of adrenal insufficiency after COVID-19 infection, confirmed by an abnormal cortisol response to a highdose ACTH stimulation test. The markedly elevated ACTH level, inappropriately low aldosterone level, and the presence of 21-hydroxylase antibodies support the diagnosis of AAI. Addison's disease is a primary adrenocortical deficiency resulting from damage to the adrenal cortex (7, 8) , which does not become clinically apparent until 80 to 90% of both adrenal cortices are destroyed (9) . Causes of Addison's disease include infections, infiltration, and hemorrhage, and most commonly in Western countries, autoimmunity (7) . In our patient, clinical hypoadrenalism did not manifest until after her COVID-19 infection, which raises the question as to a potential link between them. AI associated with COVID-19 infection has been previously reported in the literature in context of adrenal hemorrhage or infarction. In one example, a 70-year-old woman presented with fever, cough, fatigue, abdominal pain, and nausea (6) . Serology for COVID-19 was positive. Hypotension and serum chemistry with hyponatremia was concerning for AI. In the setting of acute abdominal complaints, abdominopelvic CT scan was performed, revealing enlarged, diffusely hypoattenuating adrenal glands with poor enhancement, suggestive of nonhemorrhagic adrenal infarction. In a second case, a 69-year-old man presented for fever and abdominal pain (5) . Similarly, he was positive for COVID-19 and was found to be hyponatremic. Abdominal CT scan demonstrated bilateral adrenal hemorrhage. COVID-19 has been known to cause a hypercoagulable state, which makes highly vascularized organs such as the adrenal glands, susceptible to infarction and hemorrhage (10) . Imaging of our patient's adrenal glands was unremarkable (Figure 1 ), suggestive that her AI was not related to infarction or hemorrhage. Anti-21-hydroxylase antibodies are present in >90% of AAI cases, and it serves as a sensitive and specific marker for AI, with its detection strongly associated with autoimmune destruction of the adrenal cortex (8) . Despite being a reliable marker for the disease, these antibodies are not thought to directly mediate the disease and the pathology of AAI, and as such the biochemical mechanism of AAI is yet to be fully elucidated. Dawoodji et al (8) identified 21hydroxylase-specific T cells in patients with AAI and determined that these cells may be related to disease progression. Like with AAI, the pathogenesis of many autoimmune conditions remain unclear but an interplay between genetic predisposition and environmental factors, such as viral and bacterial infection, are thought to play a major role (9, 11, 12) . Certain viruses could partake in development of AAI either by infecting steroid hormone-producing cells of the adrenal cortex or by affecting the balance of the immune system (9) . Autoimmunity can be induced by infectious agents via varying mechanisms, such as epitope spreading, standard activation, and autoinflammatory activation of innate immunity, to name a few (12) . Specifically, SARS-CoV-2 has been shown to produce viral amino acid sequences homologous to ACTH, however, antibodies produced to counteract these sequences destroy the host's ACTH and blunts cortisol response, which would cause secondary rather than primary AI. Additionally, infections can also J o u r n a l P r e -p r o o f target the site of autoimmune inflammation and amplify the immune disease instead of being directly responsible for induction of autoimmunity (12) . The precise methods by which COVID-19 negatively impacts adrenal function are not yet fully elucidated. The development of AAI is an insidious process with a long subclinical phase, with symptoms of hypercortisolism appearing years after adrenal gland destruction begins (8, 9) . As such, it is challenging to identify an acute or subacute infectious etiology that could have a role in the pathogenesis of AAI (14) . Preclinical adult patients with 21-hydroxylase antibodies have an approximately 20% risk of developing overt Addison's disease (8) . Our patient's past medical history of hypothyroidism predisposes her to the development of additional autoimmune conditions and polyglandular disorders (13) . However, patients with an initial diagnosis of autoimmune thyroid disease without a family history of polyglandular disorders have a relatively low probability of developing additional autoimmune disorders, when compared with patients whose initial diagnosis is a less common disorder (14, 15) . Up to 40-50% of patients with an initial diagnosis of Addison's disease go on to develop a second endocrinopathy (14, 15) . Despite the predisposition, twenty or more years can elapse between the onset of two different endocrinopathies (14) . A variety of factors can trigger autoimmune disease and one disorder can have multiple triggering factors (15) . Whether our patient's COVID-19 infection was a causal event for the development of AAI, or whether the viral infection had a role in furthering the development of clinically significant AI remains unclear. Infections can also target the site of autoimmune inflammation and amplify the immune disease instead of being directly responsible for induction of autoimmunity (12) . It is a strong possibility that our patient had 21-hydroxylase antibodies and ongoing adrenal cortex destruction prior to contracting COVID-19, but the rapid progression J o u r n a l P r e -p r o o f to clinically significant AI after the infection brings to question whether the infection served to target her adrenal glands as a site of autoimmune inflammation, serving as a catalyst to the clinical presentation of her AAI. In susceptible patients, such as those with previously known endocrinopathies, COVID-19 infection may promote the development or progression of clinically significant adrenal insufficiency, through adrenal hemorrhage or infarction, or via autoimmunity. Given the severity of undiagnosed hypocortisolism and our current understanding of the various mechanism by which COVID-19 can cause AI, it is important to have AI as a differential diagnosis in patients with the proper clinical scenario during or after a COVID-19 infection. The Impact of COVID-19 Vital Infection on the Hypothalamic-Pituitary-Adrenal Axis New onset adrenal insufficiency in a patient with COVID-19 Effect of COVID-19 on the Organs COVID-19 and the endocrine system: exploring the unexplored Adrenal insufficiency in coronavirus disease 2019: a case report A case of adrenal infarction in a patient with COVID-19 infection Infectious Causes of Adrenal Insufficiency High Frequency of Cytolytic 21-Hydroxylase-Specific CD8 + T Cells in Autoimmune Addison's Disease Patients The potential role of infections in the pathogenesis of autoimmune Addison's disease Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease A Potential Link between Environmental Triggers and Autoimmunity Addison's disease in a patient with hypothyroidism: autoimmune polyglandular syndrome type 2 Autoimmune polyendocrine syndromes Autoimmune Polyendocrine Syndromes The case detailed here was previously accepted for an abstract at the 2021 American Association of Clinic Endocrinologists annual conference.